Transcriptional regulation of UCP4 by NF-κB and its role in mediating protection against MPP+ toxicity

Free Radical Biology and Medicine

Volumn 49, Issue 2, 2010, Pages 192-204

  Ho, Jessica Wing Man ^a   Ho, Philip Wing Lok ^a   Zhang, Wei Yi ^a   Liu, Hui Fang ^a   Kwok, Ken Hon Hung ^a   Yiu, David Chi Wai ^a   Chan, Koon Ho ^a   Kung, Michelle Hiu Wai ^a   Ramsden, David Boyer ^b   Ho, Shu Leong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Free radicals; Mitochondrial dysfunction; Nuclear factor B; Oxidative stress; Parkinson disease; Promoter; Transcription regulation; UCP; Uncoupling protein 4

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 4 HYDROXYNONENAL; CYCLOHEXIMIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN; UNCOUPLING PROTEIN 4;

ARTICLE; BINDING SITE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

EID: 77953544163     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.04.002     Document Type: Article

References (59)

1. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 1990, 55:2142-2145.
2. Mizuno Y., Ikebe S., Hattori N., Nakagawa-Hattori Y., Mochizuki H., Tanaka M., Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim. Biophys. Acta 1995, 1271:265-274.
3. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
4. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
5. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 1996, 735:159-168.
6. Clemens J.A., Stephenson D.T., Smalstig E.B., Dixon E.P., Little S.P. Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. Stroke 1997, 28:1073-1080. (discussion 1080-1071).
7. Bethea J.R., Castro M., Keane R.W., Lee T.T., Dietrich W.D., Yezierski R.P. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J. Neurosci. 1998, 18:3251-3260.
8. Schneider A., Martin-Villalba A., Weih F., Vogel J., Wirth T., Schwaninger M. NF-κB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 1999, 5:554-559.
9. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 1997, 94:7531-7536.
10. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 1997, 94:2642-2647.
11. Nicholls D.G., Locke R.M. Thermogenic mechanisms in brown fat. Physiol. Rev. 1984, 64:1-64.
12. Mao W., Yu X.X., Zhong A., Li W., Brush J., Sherwood S.W., Adams S.H., Pan G. UCP4, a novel brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett. 1999, 443:326-330.
13. Sanchis D., Fleury C., Chomiki N., Goubern M., Huang Q., Neverova M., Gregoire F., Easlick J., Raimbault S., Levi-Meyrueis C., Miroux B., Collins S., Seldin M., Richard D., Warden C., Bouillaud F., Ricquier D. BMCP1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast. J. Biol. Chem. 1998, 273:34611-34615.
14. Fleury C., Neverova M., Collins S., Raimbault S., Champigny O., Levi-Meyrueis C., Bouillaud F., Seldin M.F., Surwit R.S., Ricquier D., Warden C.H. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 1997, 15:269-272.
15. + toxicity in neuronal cells. Neurotox. Res. 2009, 17:332-343.
16. Andrews Z.B., Horvath B., Barnstable C.J., Elsworth J., Yang L., Beal M.F., Roth R.H., Matthews R.T., Horvath T.L. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J. Neurosci. 2005, 25:184-191.
17. Echtay K.S., Roussel D., St-Pierre J., Jekabsons M.B., Cadenas S., Stuart J.A., Harper J.A., Roebuck S.J., Morrison A., Pickering S., Clapham J.C., Brand M.D. Superoxide activates mitochondrial uncoupling proteins. Nature 2002, 415:96-99.
18. Horimoto M., Fulop P., Derdak Z., Wands J.R., Baffy G. Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology 2004, 39:386-392.
19. Vidal-Puig A.J., Grujic D., Zhang C.Y., Hagen T., Boss O., Ido Y., Szczepanik A., Wade J., Mootha V., Cortright R., Muoio D.M., Lowell B.B. Energy metabolism in uncoupling protein 3 gene knockout mice. J. Biol. Chem. 2000, 275:16258-16266.
20. Ho P.W., Chan D.Y., Kwok K.H., Chu A.C., Ho J.W., Kung M.H., Ramsden D.B., Ho S.L. Methyl-4-phenylpyridinium ion modulates expression of mitochondrial uncoupling proteins 2, 4, and 5 in catecholaminergic (SK-N-SH) cells. J. Neurosci. Res. 2005, 81:261-268.
21. +-induced mitochondrial membrane depolarization, ATP deficiency, and oxidative cytotoxicity. J. Neurosci. Res. 2006, 84:1358-1366.
22. +- and dopamine-induced oxidative stress, mitochondrial depolarization, and ATP deficiency in neurons and is interlinked with UCP2 expression. Free Radic. Biol. Med. 2009, 46:810-820.
23. Mizuno Y., Sone N., Saitoh T. Effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 1987, 48:1787-1793.
24. + induced substantia nigra degeneration is attenuated in nNOS knockout mice. Neurobiol. Dis. 1997, 4:114-121.
25. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 1997, 174:193-197.
26. 2+ through uncoupling proteins. Antioxid. Redox Signaling 2009, 11:1805-1818.
27. Chan S.L., Liu D., Kyriazis G.A., Bagsiyao P., Ouyang X., Mattson M.P. Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells. J. Biol. Chem. 2006, 281:37391-37403.
28. Liu D., Chan S.L., de Souza-Pinto N.C., Slevin J.R., Wersto R.P., Zhan M., Mustafa K., de Cabo R., Mattson M.P. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. Neuromol. Med. 2006, 8:389-414.
29. Kaltschmidt B., Baeuerle P.A., Kaltschmidt C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol. Aspects Med. 1993, 14:171-190.
30. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
31. Lipton S.A. Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat. Med. 1997, 3:20-22.
32. Pande V., Sharma R.K., Inoue J., Otsuka M., Ramos M.J. A molecular modeling study of inhibitors of nuclear factor kappa-B (p50)-DNA binding. J. Comput. Aided Mol. Des. 2003, 17:825-836.
33. Pizzi M., Sarnico I., Boroni F., Benarese M., Steimberg N., Mazzoleni G., Dietz G.P., Bahr M., Liou H.C., Spano P.F. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ. 2005, 12:761-772.
34. + toxicity in SK-N-SH cells. J. Neural Transm. 2008, 115:669-676.
35. L. Mol. Cell. Biol. 2000, 20:2687-2695.
36. Bernard D., Quatannens B., Begue A., Vandenbunder B., Abbadie C. Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res. 2001, 61:2656-2664.
37. + induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways. J. Neuropathol. Exp. Neurol. 2003, 62:1144-1153.
38. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88:494-501.
39. Saxonov S., Berg P., Brutlag D.L. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl. Acad. Sci. USA 2006, 103:1412-1417.
40. Kozak U.C., Kopecky J., Teisinger J., Enerback S., Boyer B., Kozak L.P. An upstream enhancer regulating brown-fat-specific expression of the mitochondrial uncoupling protein gene. Mol. Cell. Biol. 1994, 14:59-67.
41. Tu N., Chen H., Winnikes U., Reinert I., Marmann G., Pirke K.M., Lentes K.U. Molecular cloning and functional characterization of the promoter region of the human uncoupling protein-2 gene. Biochem. Biophys. Res. Commun. 1999, 265:326-334.
42. Yoshitomi H., Yamazaki K., Tanaka I. Mechanism of ubiquitous expression of mouse uncoupling protein 2 mRNA: control by cis-acting DNA element in 5′-flanking region. Biochem. J. 1999, 340(Pt 2):397-404.
43. Courey A.J., Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 1988, 55:887-898.
44. Emami K.H., Burke T.W., Smale S.T. Sp1 activation of a TATA-less promoter requires a species-specific interaction involving transcription factor IID. Nucleic Acids Res. 1998, 26:839-846.
45. Valerio D., Duyvesteyn M.G., Dekker B.M., Weeda G., Berkvens T.M., van der Voorn L., van Ormondt H., van der Eb A.J. Adenosine deaminase: characterization and expression of a gene with a remarkable promoter. EMBO J. 1985, 4:437-443.
46. Andrews Z.B., Diano S., Horvath T.L. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat. Rev. Neurosci. 2005, 6:829-840.
47. Taglialatela G., Robinson R., Perez-Polo J.R. Inhibition of nuclear factor kappa B (NFkappaB) activity induces nerve growth factor-resistant apoptosis in PC12 cells. J. Neurosci. Res. 1997, 47:155-162.
48. Massa P.T., Aleyasin H., Park D.S., Mao X., Barger S.W. NFkappaB in neurons? The uncertainty principle in neurobiology. J. Neurochem. 2006, 97:607-618.
49. Grilli M., Memo M. Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem. Pharmacol. 1999, 57:1-7.
50. Boersma M.C., Meffert M.K. Novel roles for the NF-kappaB signaling pathway in regulating neuronal function. Sci. Signaling 2008, 1(pe7).
51. Romano A., Freudenthal R., Merlo E., Routtenberg A. Evolutionarily-conserved role of the NF-kappaB transcription factor in neural plasticity and memory. Eur. J. Neurosci. 2006, 24:1507-1516.
52. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem. Res. 2005, 30:883-893.
53. Pizzi M., Goffi F., Boroni F., Benarese M., Perkins S.E., Liou H.C., Spano P. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J. Biol. Chem. 2002, 277:20717-20723.
54. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. USA 2005, 102:19126-19131.
55. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
56. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N. Engl. J. Med. 1983, 309:310.
57. Noda Y., Sumino T., Fujisawa Y., Miyata N., Kaiya T., Kohda K. 1-Amino-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 1-amino-4-phenylpyridinium salt, the 1-amino analogues of neurotoxins, MPTP and MPP+, induce apoptosis in PC12 cells: detection of apoptotic cells by comet assay and flow cytometric analysis. In Vivo 2004, 18:561-569.
58. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 1983, 80:4546-4550.
59. + in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008, 22:2488-2497.